Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink Data.

Stolz D, Kostikas K, Loefroth E, Fogel R, Gutzwiller FS, Conti V, Cao H, Clemens A.

Chest. 2019 May 16. pii: S0012-3692(19)31055-4. doi: 10.1016/j.chest.2019.04.107. [Epub ahead of print]

PMID:
31103696
2.

Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.

Xiong Y, Pigeolet E, Mulyukov Z, Margaron P, Racine A, Clemens A.

Contemp Clin Trials. 2019 May;80:34-39. doi: 10.1016/j.cct.2019.03.008. Epub 2019 Mar 21.

3.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

4.

Estrus-Cycle Regulation of Cortical Inhibition.

Clemens AM, Lenschow C, Beed P, Li L, Sammons R, Naumann RK, Wang H, Schmitz D, Brecht M.

Curr Biol. 2019 Feb 18;29(4):605-615.e6. doi: 10.1016/j.cub.2019.01.045. Epub 2019 Feb 7.

PMID:
30744972
5.

Multisensory and Motor Representations in Rat Oral Somatosensory Cortex.

Clemens AM, Fernandez Delgado Y, Mehlman ML, Mishra P, Brecht M.

Sci Rep. 2018 Sep 10;8(1):13556. doi: 10.1038/s41598-018-31710-0.

6.

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):660-669. doi: 10.1002/psp4.12322. Epub 2018 Aug 15.

7.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

8.

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.

Kostikas K, Aalamian-Mattheis M, Pagano VA, Nunez X, Fogel R, Patalano F, Clemens A.

COPD. 2018 Apr;15(2):185-191. doi: 10.1080/15412555.2018.1445213. Epub 2018 Apr 16. Erratum in: COPD. 2018 Jun;15(3):313.

PMID:
29658810
9.

Impact of Thermal Degradation of Cyanidin-3-O-Glucoside of Haskap Berry on Cytotoxicity of Hepatocellular Carcinoma HepG2 and Breast Cancer MDA-MB-231 Cells.

Pace E, Jiang Y, Clemens A, Crossman T, Rupasinghe HPV.

Antioxidants (Basel). 2018 Jan 27;7(2). pii: E24. doi: 10.3390/antiox7020024.

10.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

11.

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.

Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.

Respir Res. 2017 Jan 11;18(1):13. doi: 10.1186/s12931-016-0498-1.

12.

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.

Klok FA, Hösel V, Clemens A, Yollo WD, Tilke C, Schulman S, Lankeit M, Konstantinides SV.

Eur Respir J. 2016 Nov;48(5):1369-1376. doi: 10.1183/13993003.00280-2016. Epub 2016 Jul 28.

13.

Simultaneous removal of rotavirus and adenovirus from artificial ground water using hydrochar derived from swine feces.

Chung JW, Breulmann M, Clemens A, Fühner C, Foppen JW, Lens PN.

J Water Health. 2016 Oct;14(5):754-767.

PMID:
27740542
14.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).

Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L.

Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.

PMID:
27496855
15.

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).

Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1425-34. doi: 10.2147/COPD.S106127. eCollection 2016.

16.

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).

Hermans M, Van Gaal L, Rézette I, Daci E, MacDonald K, Denhaerynck K, Vancayzeele S, De Meester L, Clemens A, Yee B, Abraham I.

Prim Care Diabetes. 2016 Dec;10(6):425-433. doi: 10.1016/j.pcd.2016.05.008. Epub 2016 Jul 4.

PMID:
27388795
17.

The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?

Kostikas K, Clemens A, Patalano F.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 16;11:1297-306. doi: 10.2147/COPD.S107307. eCollection 2016. Review.

18.

Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.

Kolaczynski WM, Hankins M, Ong SH, Richter H, Clemens A, Toussi M.

Diabetes Ther. 2016 Sep;7(3):483-96. doi: 10.1007/s13300-016-0177-8. Epub 2016 Jun 4.

19.

Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.

Samama CM, Rosencher N, Kleine E, Feuring M, Brueckmann M, Clemens A, Gullberg J, Frostick SP.

Thromb Res. 2016 Jul;143:103-10. doi: 10.1016/j.thromres.2016.05.014. Epub 2016 May 14.

PMID:
27208980
20.

Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease.

Kooiman J, van der Hulle T, Maas H, Wiebe S, Formella S, Clemens A, van Buren M, Janssen M, Rabelink TJ, Huisman MV.

J Am Coll Cardiol. 2016 May 24;67(20):2442-2444. doi: 10.1016/j.jacc.2016.03.516. No abstract available.

21.

Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.

Malhotra R, Babhulkar S, Sanjib KB, Clemens A, Dadi A, Iyer R, Kamath S, Mody B, Mutha S, Reddy G, Shah V, Shah V, Shetty N, Tapasvi S, Wadhwa M.

Asian J Surg. 2017 Apr;40(2):145-151. doi: 10.1016/j.asjsur.2015.10.007. Epub 2016 Apr 30.

22.

Prediction and prevention of exacerbations and mortality in patients with COPD.

Kostikas K, Clemens A, Patalano F.

Expert Rev Respir Med. 2016 Jul;10(7):739-53. doi: 10.1080/17476348.2016.1185371. Epub 2016 May 20. Review.

PMID:
27135786
23.

Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting.

Rosencher N, Samama CM, Feuring M, Brueckmann M, Kleine E, Clemens A, Frostick S.

Thromb J. 2016 Apr 1;14:8. doi: 10.1186/s12959-016-0082-4. eCollection 2016.

24.

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.

Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener HC, Wallentin L, Yusuf S, Connolly SJ.

Europace. 2016 Jul;18(7):973-8. doi: 10.1093/europace/euv312. Epub 2016 Mar 3.

25.

Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.

Wurnig C, Clemens A, Rauscher H, Kleine E, Feuring M, Windhager R, Grohs J.

Thromb J. 2015 Nov 26;13:37. doi: 10.1186/s12959-015-0066-9. eCollection 2015.

26.

Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.

Eriksson BI, Dahl OE, Rosencher N, Clemens A, Hantel S, Feuring M, Kreuzer J, Huo M, Friedman RJ.

Thromb J. 2015 Nov 17;13:36. doi: 10.1186/s12959-015-0067-8. eCollection 2015.

27.

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.

Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F.

Thromb Haemost. 2016 Mar;115(3):562-9. doi: 10.1160/TH15-07-0531. Epub 2015 Oct 15.

PMID:
26467062
28.

Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).

Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, Connolly SJ, Yusuf S, Ezekowitz MD.

Am J Cardiol. 2015 Oct 15;116(8):1204-9. doi: 10.1016/j.amjcard.2015.07.032. Epub 2015 Jul 28.

PMID:
26282726
29.

Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis-A simulation analysis.

Liesenfeld KH, Gruenenfelder F, Clemens A.

J Clin Pharmacol. 2016 May;56(5):597-608. doi: 10.1002/jcph.620. Epub 2015 Nov 5.

PMID:
26272714
30.

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.

Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS.

Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.

PMID:
26093161
31.

Induction of apoptosis in human cancer cells by targeting mitochondria with gold nanoparticles.

Mkandawire MM, Lakatos M, Springer A, Clemens A, Appelhans D, Krause-Buchholz U, Pompe W, Rödel G, Mkandawire M.

Nanoscale. 2015 Jun 28;7(24):10634-40. doi: 10.1039/c5nr01483b. Epub 2015 May 29.

PMID:
26022234
32.

Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues.

Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, Yan R, Hu CT, Guo H, Block TM, Song W, Su YH.

Sci Rep. 2015 May 22;5:10478. doi: 10.1038/srep10478.

33.

Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP.

Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28. Review.

34.

Dabigatran Users With Non-Valvular Atrial Fibrillation in the Us: A Characterization of Dabigatran Initiators and Switchers.

Shash D, Schnee J, Schneider G, Schoof N, Zint K, Clemens A, Bartels DB.

Value Health. 2014 Nov;17(7):A499. doi: 10.1016/j.jval.2014.08.1498. Epub 2014 Oct 26. No abstract available.

35.

Critical Appraisal Of Network Meta-Analyses Evaluating The Efficacy And Safety Of New Oral Anticoagulants In Atrial Fibrillation Stroke Prevention Trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen J.

Value Health. 2014 Nov;17(7):A475-6. doi: 10.1016/j.jval.2014.08.1362. Epub 2014 Oct 26. No abstract available.

36.

A yeast pheromone-based inter-species communication system.

Hennig S, Clemens A, Rödel G, Ostermann K.

Appl Microbiol Biotechnol. 2015 Feb;99(3):1299-308. doi: 10.1007/s00253-014-6133-5. Epub 2014 Oct 21.

PMID:
25331280
37.

Outbreak of type E foodborne botulism linked to traditionally prepared salted fish in Ontario, Canada.

Walton RN, Clemens A, Chung J, Moore S, Wharton D, Haydu L, de Villa E, Sanders G, Bussey J, Richardson D, Austin JW.

Foodborne Pathog Dis. 2014 Oct;11(10):830-4. doi: 10.1089/fpd.2014.1783. Epub 2014 Sep 4.

PMID:
25188279
38.

Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?

Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY.

Ann Med. 2014 Dec;46(8):672-8. doi: 10.3109/07853890.2014.952327. Epub 2014 Aug 31.

PMID:
25174259
39.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S.

Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

40.

Bipolar sealing of lung parenchyma: tests in an ex vivo model.

Kirschbaum A, Clemens A, Steinfeldt T, Pehl A, Meyer C, Bartsch DK.

Surg Endosc. 2015 Jan;29(1):127-32. doi: 10.1007/s00464-014-3664-x. Epub 2014 Jul 16.

PMID:
25027470
41.

Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.

Clemens A, Noack H, Brueckmann M, Lip GY.

PLoS One. 2014 Jun 9;9(6):e99276. doi: 10.1371/journal.pone.0099276. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109437.

42.

The Theobroma cacao B3 domain transcription factor TcLEC2 plays a duel role in control of embryo development and maturation.

Zhang Y, Clemens A, Maximova SN, Guiltinan MJ.

BMC Plant Biol. 2014 Apr 24;14:106. doi: 10.1186/1471-2229-14-106.

43.

Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.

van Ryn J, Schurer J, Kink-Eiband M, Clemens A.

Anesthesiology. 2014 Jun;120(6):1429-40. doi: 10.1097/ALN.0000000000000255.

PMID:
24714118
44.

Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.

Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB.

Am Heart J. 2014 Mar;167(3):329-34. doi: 10.1016/j.ahj.2013.12.006. Epub 2013 Dec 19.

PMID:
24576516
45.

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes.

Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB.

BMJ Open. 2014 Jan 27;4(1):e003839. doi: 10.1136/bmjopen-2013-003839.

46.

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US.

Schoof N, Schnee J, Schneider G, Gawlik M, Zint K, Clemens A, Bartels DB.

Curr Med Res Opin. 2014 May;30(5):795-804. doi: 10.1185/03007995.2013.879529. Epub 2014 Jan 16.

PMID:
24392958
47.

Age- and location-dependent differences in store depletion-induced h-channel plasticity in hippocampal pyramidal neurons.

Clemens AM, Johnston D.

J Neurophysiol. 2014 Mar;111(6):1369-82. doi: 10.1152/jn.00839.2013. Epub 2013 Dec 31.

48.

Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.

Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S.

Thromb Haemost. 2014 May 5;111(5):933-42. doi: 10.1160/TH13-09-0734. Epub 2013 Dec 11.

PMID:
24326736
49.

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.

Clemens A, Fraessdorf M, Friedman J.

Vasc Health Risk Manag. 2013;9:599-615. doi: 10.2147/VHRM.S49830. Epub 2013 Oct 11. Review.

50.

Water desorption from nanostructured graphite surfaces.

Clemens A, Hellberg L, Grönbeck H, Chakarov D.

Phys Chem Chem Phys. 2013 Dec 21;15(47):20456-62. doi: 10.1039/c3cp52554f. Epub 2013 Sep 10.

PMID:
24018989

Supplemental Content

Loading ...
Support Center